血液系统恶性肿瘤细胞免疫治疗的研究进展

doi:10.11904/j.issn.1002-3070.2016.01.013

Abstract

Abstract: In recent years,considerable progress has been made in the treatment of hematologic malignancies.However,most patients will eventually relapse and suffer from severe side effects caused by chemotherapy or radiation.Thus,as a well tolerated,safe,effective and innovative therapy,adoptive cellular immunotherapy emerges at this very moment.This therapy can kill tumors or control recurrence by reinfusing the in vitro amplificated or treated immune effective cells into the patients.It has been actively used in the treatment of various hematological malignancies and achieved significant effects,which brings hope for more and more patients with relapsed or refractory hematological diseases.

Key words: Hematological malignancies, Cellular immunotherapy, CIK cells, NK cells, CART

CLC Number:

R730.51

HUANG Juanjuan, WANG Wenxin, CAO Fenglin. Research progress of cellular immunotherapy for hematological malignancies[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 61-65.

References

1 Sangiolo D,Martinuzzi E,Todorovic M,et al.Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer(CIK)cells:implications for their infusion across major HLA barriers[J].Int Immunol,2008,20(7):841-848.
2 Kornacker M,Moldenhauer G,Herbst M,et al.Cytokine-induced killer cells against autologous CLL:direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma[J].Int J Cancer,2006,119(6):1377-1382.
3 Pievani A,Borleri G,Pende D,et al.Dual-functional capability of CD3+CD56+CIK cells,a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity[J].Blood,2011,118(12):3301-3310.
4 Wang Y,Bo J,Dai HR,et al.CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo[J].Exp Hematol,2013,41(3):241-52.
5 Linn YC,Yong HX,Niam M,et al.A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission[J].Cytotherapy,2012,14(7):851-859.
6 Lu XC,Yang B,Yu RL,et al.Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma[J].Cell Biochem Biophys,2012,62(1):257-265.
7 Cai LL,Yang Y,Yang B,et al.Short-term curative efficacy of autologous cytokine induced killer cells combined with low-dose IL-2 regimen containing immune enhancement by thymic peptide in elderly patients with B-cell chronic lymphocytic leukemia(in Chinese)[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2012,20(3):564-570.
8 Yang B,Wang J,Cai LL,et al.Treatment of multiple solitary plasmacytomas with cytokine-induced killer cells[J].Cytotherapy,2014,16(2):278-284.
9 Yang B,Lu XC,Yu RL,et al.Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients:A pilot clinical trial[J].Hematol Oncol,2012,30(3):115-122.
10 Thanendrarajan S,Nowak M,Abken H,et al.Combining cytokine-induced killer cells with vaccination in cancer immunotherapy:More than one plus one[J].Leuk Res,2011,35(9):1136-1142.
11 Zheng Z,Yuna Z,Huimin Z,et al.Clinical study of DC-CIK(dendritic cells and cytokine-induced killer cells)eliminate minimal residual leukemia[J].Blood,2013,122(6):1450-1461.
12 Zhou DF,Zhai LN,Pan F,et al.Co-cultured dendritic cell and cytokine-induced killer cell adaptive immunotherapy for treating of childhood acute leukemia[J].Pediatric Clin Practical Mag,2012,27(3):166-169.
13 Zhong GC,Yan B,Sun Y,et al.Clinical efficacy of immunotherapy of dendritic cell and cytokine-induced killer cell combined with chemotherapy for treatment of multiple myeloma(in Chinese)[J].Zhonghua Xue Ye Xue Za Zhi,2012,33(12):1000-1003.
14 Benjamin J,Laport GG,Tate K,et al.Early infusion of donor-derived CIK cells as consolidative immunotherapy following non-myeloablative allogeneic transplantation:safety and feasibility[J].Blood,2013,122(6):899-912.
15 Zhou X,Zhu J,Sun H,et al.Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting[J].Leukemia Lymphoma,2013,54(1):209-211.
16 Linn YC,Niam M,Chu S,et al.The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies[J].Bone Marrow Transplant,2012,47(7):957-966.
17 Knorr DA,Bachanova V,Verneris MR,et al.Clinical utility of natural killer cells in cancer therapy and transplantation[J].Semin Immunol,2014,26(2):161-172.
18 Cheng M,Chen Y,Xiao W,et al.NK cell-based immunotherapy for malignant diseases[J].Cell Mol Immunol,2013,10(3):230-252.
19 Venstrom JM,Dupont B,Hsu KC,et al.Donor activating KIR2DS1 in leukemia[J].N Engl J Med,2014,371(21):2042-2051.
20 Zhang J,Basher F,Wu JD,et al.NKG2D ligands in tumor immunity:two sides of a coin[J].Front Immunol,2015,6:97.
21 Parkhurst MR,Riley JP,Dudley ME,et al.Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression[J].Clin Cancer Res,2011,17(19):6287-6297.
22 Bachanova V,Miller JS.NK cells in therapy of cancer[J].Crit Rev Oncog,2014,19(1-2):133-141.
23 Miller JS,Rooney CM,Curtsinger J,et al.Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration:implications for clinical therapy[J].Biol Blood Marrow Transplant,2014,20(8):1252-1257.
24 Cooley S,Weisdorf DJ,Guethlein LA,et al.Donor killer cell Ig-like receptor B haplotypes,recipient HLA-C1,and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia[J].J Immunol,2014,192(10):4592-4600.
25 Benjamin JE,Gill S,Negrin RS.Biology and clinical effects of natural killer cells in allogeneic transplantation[J].Curr Opin Oncol,2010,22(2):130-137.
26 Curti A,Ruggeri L,D′Addio A,et al.Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients[J].Blood,2011,118(12):3273-3279.
27 Shi J,Tricot G,Szmania S,et al.Infusion of haplo-identical killer immunoglobulin-like receptor ligand mis-matched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation[J].Br J Haematol,2008,143(5):641-653.
28 Kalos M,June CH.Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology[J].Immunity,2013,39(1):49-60.
29 Porter DL,Levine BL,Kalos M,et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med,2011,365(8):725-733.
30 Grupp SA,Kalos M,Barrett D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368(16):1509-1518.
31 Davila ML,Riviere I,Wang X,et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Sci Transl Med,2014,6(224):224-225.
32 Cruz CR,Micklethwaite KP,Savoldo B,et al.Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant:a phase 1 study[J].Blood,2013,122(17):2965-2973.
33 Lee DW,Gardner R,Porter DL,et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124(2):188-195.

[1]	ZHANG Likun,CAO Fenglin. Effect of autologous cytokine induced killer cell therapy in patients with lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 342-346.
[2]	YUAN Yutao,LIANG Xiaoliang,ZHANG Jing,HUANG Lianjiang,WANG Zhihua. Effects of IL-24 on cytotoxic activity of cytokine-induced killer cells in vivo [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(6): 525-527.
[3]	WANG Qian,ZHANG Yuegui,HUANG Sunhui,LU Shan,LI Fengqin. Nursing care for malignant tumour patients treated with autologous CIK cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(6): 561-563.
[4]	LIU Fang,YU Yan,ZHANG Hua.. Cost-effectiveness analysis of chemotherapy combined with autologous CIK cells transfusion in the treatment of aging advanced non-small-cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(4): 336-339.

Research progress of cellular immunotherapy for hematological malignancies

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments